Medacta Group SA
SIX:MOVE
US |
Fubotv Inc
NYSE:FUBO
|
Media
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
US |
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
|
CN |
NIO Inc
NYSE:NIO
|
Automobiles
|
|
US |
Fluor Corp
NYSE:FLR
|
Construction
|
|
US |
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
|
US |
TopBuild Corp
NYSE:BLD
|
Consumer products
|
|
US |
Abbott Laboratories
NYSE:ABT
|
Health Care
|
|
US |
Chevron Corp
NYSE:CVX
|
Energy
|
|
US |
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
|
US |
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
|
US |
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
|
US |
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
|
US |
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
108.4
134
|
Price Target |
|
We'll email you a reminder when the closing price reaches CHF.
Choose the stock you wish to monitor with a price alert.
Fubotv Inc
NYSE:FUBO
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
C
|
C3.ai Inc
NYSE:AI
|
US |
Uber Technologies Inc
NYSE:UBER
|
US | |
NIO Inc
NYSE:NIO
|
CN | |
Fluor Corp
NYSE:FLR
|
US | |
Jacobs Engineering Group Inc
NYSE:J
|
US | |
TopBuild Corp
NYSE:BLD
|
US | |
Abbott Laboratories
NYSE:ABT
|
US | |
Chevron Corp
NYSE:CVX
|
US | |
Occidental Petroleum Corp
NYSE:OXY
|
US | |
Matrix Service Co
NASDAQ:MTRX
|
US | |
Automatic Data Processing Inc
NASDAQ:ADP
|
US | |
Qualcomm Inc
NASDAQ:QCOM
|
US | |
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one MOVE stock under the Base Case scenario is 120.15 CHF. Compared to the current market price of 110.8 CHF, Medacta Group SA is Undervalued by 8%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Medacta Group SA
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for MOVE cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Economic Moat
Medacta Group SA
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Medacta Group SA
Balance Sheet Decomposition
Medacta Group SA
Current Assets | 364.3m |
Cash & Short-Term Investments | 21.7m |
Receivables | 118.4m |
Other Current Assets | 224.2m |
Non-Current Assets | 367.5m |
Long-Term Investments | 892k |
PP&E | 291.7m |
Intangibles | 49.7m |
Other Non-Current Assets | 25.2m |
Current Liabilities | 165.8m |
Accounts Payable | 44.1m |
Accrued Liabilities | 32.3m |
Other Current Liabilities | 89.4m |
Non-Current Liabilities | 221.9m |
Long-Term Debt | 160.3m |
Other Non-Current Liabilities | 61.6m |
Earnings Waterfall
Medacta Group SA
Revenue
|
544.3m
EUR
|
Cost of Revenue
|
-174.6m
EUR
|
Gross Profit
|
369.7m
EUR
|
Operating Expenses
|
-291.8m
EUR
|
Operating Income
|
78m
EUR
|
Other Expenses
|
-21.8m
EUR
|
Net Income
|
56.2m
EUR
|
Free Cash Flow Analysis
Medacta Group SA
EUR | |
Free Cash Flow | EUR |
Medacta Group's H1 2023 showcased a robust performance with top-line growth of over 21% in constant currency, reaching EUR 255 million in revenue. Adjusted EBITDA margin improved to 28.2%, even in the face of currency headwinds. The company experienced strong regional growth across Europe, North America, and the Asia Pacific, particularly in core product lines like hip and knee replacements, as well as robust growth in extremities and spine with an overall CAGR of over 15.5% since 2019. The gross profit margin stood at 68.9%, despite foreign exchange impacts. Adjusted EBIT increased by roughly 30% year-over-year to EUR 43.8 million, and profit for the period was EUR 29.1 million. Total debt remained below 1x EBITDA at EUR 127.9 million. No price cuts are expected in Australia for the second half of the year, and margin guidance suggests the first half is historically more profitable than the second.
What is Earnings Call?
MOVE Profitability Score
Profitability Due Diligence
Medacta Group SA's profitability score is 58/100. The higher the profitability score, the more profitable the company is.
Score
Medacta Group SA's profitability score is 58/100. The higher the profitability score, the more profitable the company is.
MOVE Solvency Score
Solvency Due Diligence
Medacta Group SA's solvency score is 67/100. The higher the solvency score, the more solvent the company is.
Score
Medacta Group SA's solvency score is 67/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
MOVE Price Targets Summary
Medacta Group SA
According to Wall Street analysts, the average 1-year price target for MOVE is 144.16 CHF with a low forecast of 135.34 CHF and a high forecast of 157.5 CHF.
Dividends
Current shareholder yield for MOVE is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
MOVE Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Medacta Group SA engages in the development, manufacture, and distribution of orthopedic and neurosurgical medical devices. The company is headquartered in Castel San Pietro, Ticino and currently employs 1,341 full-time employees. The company went IPO on 2019-04-04. The firm develops, manufactures and distributes orthopaedic and neurosurgical medical devices. The firm designs a number of products, such as hip products, including hip replacement, hip anatomy, hip diseases, and other products for the preparation of hip surgery; knee product, which encompasses knee anatomy, knee diseases, knee replacement, the stability of the knee and for the preparation of knee surgery; shoulder product, which includes shoulder anatomy, shoulder disease, shoulder replacement, and for the preparation of shoulder operation, and spine product, which includes products for spinal treatments, spinal anatomy and for surgery, among others. Additionally, the Company also offers training and support to healthcare professionals.
Contact
IPO
Employees
Officers
The intrinsic value of one MOVE stock under the Base Case scenario is 120.15 CHF.
Compared to the current market price of 110.8 CHF, Medacta Group SA is Undervalued by 8%.